Evidence map›Paper›PMID 39005596›Full record

ArticleIranian journal of microbiology2024

Designing the fusion protein of rotavirus VP8 and hepatitis A virus VP1 and evaluating the immunological response in BALB/c mice.

Hassan Yarmohammadi, Mohammadreza Aghasadeghi, Abbas Akhavan Sepahi, Mojtaba Hamidi-Fard, Golnaz Bahramali

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Diverse processes in rotavirus vaccine development.Human vaccines & immunotherapeutics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hassan YarmohammadiDepartment of Microbiology, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Mohammadreza AghasadeghiDepartment of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Abbas Akhavan SepahiDepartment of Microbiology, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Mojtaba Hamidi-FardDepartment of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Golnaz BahramaliDepartment of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Rotavirus and Hepatitis A virus are responsible for causing gastroenteritis and jaundice. The current vaccination approaches have proven insufficient, especially in low-income countries. In this study, we presented a novel dual-vaccine candidate that combines the rotavirus VP8 protein and the hepatitis A virus VP1. Materials and Methods: The VP8*-rotavirus+AAY+HAV-VP1 fusion protein was produced using an Results: The fusion protein, when combined with adjuvants, elicited significantly higher total IgG, IgG1, and IgG2 responses compared to VP1 and VP8 alone, as well as the rotavirus and hepatitis A vaccines. Furthermore, it induced a higher short-term IL-5 and IFN-γ response while demonstrating a higher long-term IL-5 response compared to the rotavirus and hepatitis A vaccines. Conclusion: This study demonstrates that the VP8*-rotavirus+AAY+HAV-VP1 fusion protein is a promising dual vaccine candidate for immunization against hepatitis A and rotaviruses.

Indexed as

BALB/c mouseBivalent vaccinesHepatitis A virusImmunoinformaticsRecombinant fusion proteinsRotavirus

Identifiers

PMID39005596
PMCPMC11245353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.